PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy®)
Effective Friday, May 3rd, 2024, Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd, has acquired global rights to lonafarnib (Zokinvy) from Eiger BioPharmaceuticals (Eiger). Zokinvy® is provided to families worldwide who are using the drug as a treatment for progeria.Based in San Diego, California, Sentynl is focused on providing n
May 22, 2024